<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39408857</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10530</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910530</ELocationID><Abstract><AbstractText>Interferons (IFNs) produced by airway epithelial cells are crucial in defending against pathogens. Fluctuations in IFN-λ levels may influence coronavirus disease 19 (COVID-19) severity. However, conflicting data have been reported regarding serum IFN-λ concentrations in COVID-19 patients. To address this, we evaluated serum IFN-λ levels over time in moderate and severe COVID-19 patients and their association with cytokine production and clinical parameters using the enzyme-linked immunosorbent assay (ELISA) and the Bio-Plex Pro Human Cytokine 17-plex Assay. Results from testing 51 COVID-19 patients showed that 68% lacked detectable serum IFN-λ. Among non-IFN-λ secretors, severe COVID-19 predominated. In contrast, IFN-λ secretors displayed stable IFN-λ levels in moderate cases, while severe cases showed a decline over time, which persisted even after recovery. A negative correlation was observed between IFN-λ levels and inflammatory markers. This, combined with an increase in tumor necrosis factor alpha (TNF-α) and clinical improvement, suggests a regulatory role for IFN-λ in promoting faster recovery. Despite this, survival rates were similar between the groups, indicating that while IFN-λ influences the course of the disease, it does not directly affect overall survival. In conclusion, IFN-λ is vital, but not unique, for the antiviral response and COVID-19 recovery. Simultaneously, serum IFN-λ deficiency signifies severe COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zaleska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7513-8042</Identifier><AffiliationInfo><Affiliation>Department of Allergology and Internal Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dor-Wojnarowska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1437-1668</Identifier><AffiliationInfo><Affiliation>Department of Allergology and Internal Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radlińska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Allergology and Internal Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rorat</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5318-4945</Identifier><AffiliationInfo><Affiliation>Department of Social Sciences and Infectious Diseases, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szymański</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-6605-6718</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Hepatology, Wroclaw Medical University, 50-367 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gajewski</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7445-9752</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Allergy, Medical University of Lodz, 92-213 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chałubiński</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8311-9530</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Allergy, Medical University of Lodz, 92-213 Lodz, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>STM.A200.21.060</GrantID><Agency>Ministry of Health subvention</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000624353">interferon-lambda, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000095022">Interferon Lambda</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095022" MajorTopicYN="N">Interferon Lambda</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">interferon</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39408857</ArticleId><ArticleId IdType="pmc">PMC11476353</ArticleId><ArticleId IdType="doi">10.3390/ijms251910530</ArticleId><ArticleId IdType="pii">ijms251910530</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Forman R., Shah S., Jeurissen P., Jit M., Mossialos E. COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy. 2021;125:553–567. doi: 10.1016/j.healthpol.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC7997052</ArticleId><ArticleId IdType="pubmed">33820678</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y.-D., Ding M., Dong X., Zhang J.-J., Kursat Azkur A., Azkur D., Gan H., Sun Y.-L., Fu W., Li W., et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76:428–455. doi: 10.1111/all.14657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>An P.-J., Zhu Y.Z., Yang L.-P. Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications. Pharmacol. Res. 2020;159:104946. doi: 10.1016/j.phrs.2020.104946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104946</ArticleId><ArticleId IdType="pmc">PMC7244444</ArticleId><ArticleId IdType="pubmed">32450346</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond M.S., Kanneganti T.-D. Innate immunity: The first line of defense against SARS-CoV-2. Nat. Immunol. 2022;23:165–176. doi: 10.1038/s41590-021-01091-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaender S., Mar K.B., Michailidis E., Kratzel A., Boys I.N., V’kovski P., Fan W., Kelly J.N., Hirt D., Ebert N., et al. LY6E impairs coronavirus fusion and confers immune control of viral disease. Nat. Microbiol. 2020;5:1330–1339. doi: 10.1038/s41564-020-0769-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0769-y</ArticleId><ArticleId IdType="pmc">PMC7916999</ArticleId><ArticleId IdType="pubmed">32704094</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Sancho L., Lewinski M.K., Pache L., Stoneham C.A., Yin X., Becker M.E., Pratt D., Churas C., Rosenthal S.B., Liu S., et al. Functional landscape of SARS-CoV-2 cellular restriction. Mol. Cell. 2021;81:2656–2668.e8. doi: 10.1016/j.molcel.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8043580</ArticleId><ArticleId IdType="pubmed">33930332</ArticleId></ArticleIdList></Reference><Reference><Citation>Felgenhauer U., Schoen A., Gad H.H., Hartmann R., Schaubmar A.R., Failing K., Drosten C., Weber F. Inhibition of SARS-CoV-2 by type I and type III interferons. J. Biol. Chem. 2020;295:13958–13964. doi: 10.1074/jbc.AC120.013788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC120.013788</ArticleId><ArticleId IdType="pmc">PMC7549028</ArticleId><ArticleId IdType="pubmed">32587093</ArticleId></ArticleIdList></Reference><Reference><Citation>Quarleri J., Delpino M.V. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. Cytokine Growth Factor Rev. 2021;58:55–65. doi: 10.1016/j.cytogfr.2021.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.01.003</ArticleId><ArticleId IdType="pmc">PMC7871890</ArticleId><ArticleId IdType="pubmed">33608189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.-M., Shin E.-C. Type I and III interferon responses in SARS-CoV-2 infection. Exp. Mol. Med. 2021;53:750–760. doi: 10.1038/s12276-021-00592-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00592-0</ArticleId><ArticleId IdType="pmc">PMC8099704</ArticleId><ArticleId IdType="pubmed">33953323</ArticleId></ArticleIdList></Reference><Reference><Citation>Feld J.J., Kandel C., Biondi M.J., Kozak R.A., Zahoor M.A., Lemieux C., Borgia S.M., Boggild A.K., Powis J., McCready J., et al. Peginterferon lambda for the treatment of outpatients with COVID-19: A phase 2, placebo-controlled randomised trial. Lancet Respir. Med. 2021;9:498–510. doi: 10.1016/S2213-2600(20)30566-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30566-X</ArticleId><ArticleId IdType="pmc">PMC7906707</ArticleId><ArticleId IdType="pubmed">33556319</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon K.H., Leist S.R., Schäfer A., Edwards C.E., Martinez D.R., Montgomery S.A., West A., Yount B.L., Hou Y.J., Adams L.E., et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586:560–566. doi: 10.1038/s41586-020-2708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2708-8</ArticleId><ArticleId IdType="pmc">PMC8034761</ArticleId><ArticleId IdType="pubmed">32854108</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., Moreira Silva E.A.S., Medeiros Silva D.C., Thabane L., Campos V.H.S., Ferreira T.S., Santos C.V.Q., Nogueira A.M.R., Almeida A.P.F.G., Savassi L.C.M., et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. N. Engl. J. Med. 2023;388:518–528. doi: 10.1056/NEJMoa2209760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2209760</ArticleId><ArticleId IdType="pmc">PMC9933926</ArticleId><ArticleId IdType="pubmed">36780676</ArticleId></ArticleIdList></Reference><Reference><Citation>Broggi A., Ghosh S., Sposito B., Spreafico R., Balzarini F., Lo Cascio A., Clementi N., de Santis M., Mancini N., Granucci F., et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369:706–712. doi: 10.1126/science.abc3545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc3545</ArticleId><ArticleId IdType="pmc">PMC7292499</ArticleId><ArticleId IdType="pubmed">32527925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatton C.F., Botting R.A., Dueñas M.E., Haq I.J., Verdon B., Thompson B.J., Spegarova J.S., Gothe F., Stephenson E., Gardner A.I., et al. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Nat. Commun. 2021;12:7092. doi: 10.1038/s41467-021-27318-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27318-0</ArticleId><ArticleId IdType="pmc">PMC8651658</ArticleId><ArticleId IdType="pubmed">34876592</ArticleId></ArticleIdList></Reference><Reference><Citation>Read S.A., Gloss B.S., Liddle C., George J., Ahlenstiel G. Interferon-λ3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis. J. Inflamm. Res. 2021;14:1257–1270. doi: 10.2147/JIR.S301476.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S301476</ArticleId><ArticleId IdType="pmc">PMC8021260</ArticleId><ArticleId IdType="pubmed">33833547</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekimoto Y., Sekiya M., Nojiri S., Hayakawa E., Masui Y., Tajima M., Nishino K., Nishizaki Y., Takahashi K. IFN-λ3 and CCL17 as predictors of disease progression in patients with mild to moderate COVID-19: A cohort study in a real-world setting. Respir. Investig. 2023;61:153–156. doi: 10.1016/j.resinv.2022.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resinv.2022.12.006</ArticleId><ArticleId IdType="pmc">PMC9834168</ArticleId><ArticleId IdType="pubmed">36682084</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T., Iwamoto N., Tsuzuki S., Kakumoto Y., Suzuki M., Ashida S., Oshiro Y., Nemoto T., Kanda K., Okuhama A., et al. Interferon lambda 3 in the early phase of coronavirus disease-19 can predict oxygen requirement. Eur. J. Clin. Investig. 2022;52:e13808. doi: 10.1111/eci.13808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13808</ArticleId><ArticleId IdType="pmc">PMC9541409</ArticleId><ArticleId IdType="pubmed">35506823</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda Y., Homma T., Inoue H., Onitsuka C., Ikeda H., Goto Y., Sato Y., Kimura T., Hirai K., Ohta S., et al. Downregulation of type III interferons in patients with severe COVID-19. J. Med. Virol. 2021;93:4559–4563. doi: 10.1002/jmv.26993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26993</ArticleId><ArticleId IdType="pmc">PMC8250710</ArticleId><ArticleId IdType="pubmed">33811680</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda Y., Homma T., Inoue H., Goto Y., Sato Y., Ikeda H., Onitsuka C., Sato H., Akimoto K., Ebato T., et al. Serum IL-28A/IFN-λ2 is linked to disease severity of COVID-19. Sci. Rep. 2022;12:5458. doi: 10.1038/s41598-022-09544-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-09544-8</ArticleId><ArticleId IdType="pmc">PMC8969403</ArticleId><ArticleId IdType="pubmed">35361913</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbazi M., Amri Maleh P., Bagherzadeh M., Moulana Z., Sepidarkish M., Rezanejad M., Mirzakhani M., Ebrahimpour S., Ghorbani H., Ahmadnia Z., et al. Linkage of Lambda Interferons in Protection Against Severe COVID-19. J. Interferon Cytokine Res. 2021;41:149–152. doi: 10.1089/jir.2020.0187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2020.0187</ArticleId><ArticleId IdType="pubmed">33885337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.-H., Salloum S., Wang J.Y., Wong L.P., Regan J., Lefteri K., Manickas-Hill Z., Gao C., Li J.Z., Sadreyev R.I., et al. Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity. J. Infect. Dis. 2021;224:777–782. doi: 10.1093/infdis/jiab288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab288</ArticleId><ArticleId IdType="pmc">PMC8244575</ArticleId><ArticleId IdType="pubmed">34467988</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinkhammer J., Schnepf D., Ye L., Schwaderlapp M., Gad H.H., Hartmann R., Garcin D., Mahlakõiv T., Staeheli P. IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. eLife. 2018;7:e33354. doi: 10.7554/eLife.33354.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.33354</ArticleId><ArticleId IdType="pmc">PMC5953542</ArticleId><ArticleId IdType="pubmed">29651984</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino L., Fracella M., Frasca F., D’Auria A., Santinelli L., Maddaloni L., Bugani G., Bitossi C., Gentile M., Ceccarelli G., et al. Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients. Microorganisms. 2023;11:689. doi: 10.3390/microorganisms11030689.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11030689</ArticleId><ArticleId IdType="pmc">PMC10058642</ArticleId><ArticleId IdType="pubmed">36985262</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.-C., Uhl S., Hoagland D., Møller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036–1045.e9. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Busnadiego I., Fernbach S., Pohl M.O., Karakus U., Huber M., Trkola A., Stertz S., Hale B.G. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. mBio. 2020;11:e01928-20. doi: 10.1128/mBio.01928-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01928-20</ArticleId><ArticleId IdType="pmc">PMC7484541</ArticleId><ArticleId IdType="pubmed">32913009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., Castro T.B.R., Silva J., Sundaram M., Ellingson M.K., Mao T., Oh J.E., Israelow B., et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463–469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Galani I.-E., Rovina N., Lampropoulou V., Triantafyllia V., Manioudaki M., Pavlos E., Koukaki E., Fragkou P.C., Panou V., Rapti V., et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 2021;22:32–40. doi: 10.1038/s41590-020-00840-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00840-x</ArticleId><ArticleId IdType="pubmed">33277638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tovo P.-A., Garazzino S., Daprà V., Pruccoli G., Calvi C., Mignone F., Alliaudi C., Denina M., Scolfaro C., Zoppo M., et al. COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases. Int. J. Mol. Sci. 2021;22:7481. doi: 10.3390/ijms22147481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22147481</ArticleId><ArticleId IdType="pmc">PMC8303145</ArticleId><ArticleId IdType="pubmed">34299101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridharan A., Esposo M., Kaushal K., Tay J., Osann K., Agrawal S., Gupta S., Agrawal A. Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity. Age. 2011;33:363–376. doi: 10.1007/s11357-010-9191-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-010-9191-3</ArticleId><ArticleId IdType="pmc">PMC3168606</ArticleId><ArticleId IdType="pubmed">20953722</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Hu X., Wang D., Gong R., Wang Q., Ren F., Wu Y., Chen J., Xiong X., Li H., et al. Multi-cohort study on cytokine and chemokine profiles in the progression of COVID-19. Sci. Rep. 2024;14:10324. doi: 10.1038/s41598-024-61133-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-61133-z</ArticleId><ArticleId IdType="pmc">PMC11074324</ArticleId><ArticleId IdType="pubmed">38710800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinina O., Golovkin A., Zaikova E., Aquino A., Bezrukikh V., Melnik O., Vasilieva E., Karonova T., Kudryavtsev I., Shlyakhto E. Cytokine Storm Signature in Patients with Moderate and Severe COVID-19. Int. J. Mol. Sci. 2022;23:8879. doi: 10.3390/ijms23168879.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23168879</ArticleId><ArticleId IdType="pmc">PMC9408700</ArticleId><ArticleId IdType="pubmed">36012146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims J.T., Krishnan V., Chang C.-Y., Engle S.M., Casalini G., Rodgers G.H., Bivi N., Nickoloff B.J., Konrad R.J., de Bono S., et al. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J. Allergy Clin. Immunol. 2021;147:107–111. doi: 10.1016/j.jaci.2020.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.08.031</ArticleId><ArticleId IdType="pmc">PMC7488591</ArticleId><ArticleId IdType="pubmed">32920092</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.H., Park-Min K.-H., Chen J., Hu X., Ivashkiv L.B. Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat. Immunol. 2011;12:607–615. doi: 10.1038/ni.2043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2043</ArticleId><ArticleId IdType="pmc">PMC3258532</ArticleId><ArticleId IdType="pubmed">21602809</ArticleId></ArticleIdList></Reference><Reference><Citation>Dattola A., Tolone M., Amore E., Bennardo L., Trovato F., Amato S., Grieco T., Richetta A.G., Pellacani G., Skroza N., et al. Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The role of Tralokinumab. Dermatol. Pract. Concept. 2024;14:e2024204. doi: 10.5826/dpc.1403a204.</Citation><ArticleIdList><ArticleId IdType="doi">10.5826/dpc.1403a204</ArticleId><ArticleId IdType="pmc">PMC11314215</ArticleId><ArticleId IdType="pubmed">39122503</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. National Institutes of Health (US): Bethesda, MD, USA, 2021. 21 April–29 February 2024.  [(accessed on 27 July 2024)]; Available online:  https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>